EsoGuard® test volume gains momentum as Lucid expands high-volume testing events PAVmed appoints President for Veris Health and expands commercial footprint Conference call and webcast to be held tomorrow, May 17th at 8:30 AM EST NEW YORK, May 16, 2023 /PRNewswire/ — PAVmed Inc. (NASDAQ: PAVM, PAVMZ) (“PAVmed” or the “Company”), a diversified commercial-stage medical technology company, operating in […]
Tag: PAVmed
PAVmed Provides Business Update and Preliminary Fourth Quarter and Full Year 2022 Financial Results
Conference call and webcast to be held tomorrow, March 15th at 8:30 AM EST NEW YORK, March 14, 2023 /PRNewswire/ — PAVmed Inc. (NASDAQ: PAVM, PAVMZ) (“PAVmed” or the “Company”), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid […]
PAVmed Provides Business Update and Third Quarter 2022 Financial Results
EsoGuard test volume shows steady sequential growth Veris Cancer Care Platform poised for commercial launch Conference call and webcast to be held today at 4:30 PM EDT NEW YORK–(BUSINESS WIRE)–PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and […]
PAVmed Provides Business Update and Preliminary First Quarter 2022 Financial Results
Conference call to be held today at 4:30 PM EDT NEW YORK–(BUSINESS WIRE)–PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. […]
PAVmed Chairman and Chief Executive Officer Lishan Aklog, M.D., Elected to AdvaMed Board of Directors
NEW YORK, March 01, 2021 (GLOBE NEWSWIRE) — PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced that the Advanced Medical Technology Association (AdvaMed), the world’s leading medical technology trade association, has appointed Lishan Aklog, M.D., PAVmed’s Chairman and Chief Executive […]
PAVmed Receives Formal Notification of Nasdaq Continued Listing Compliance
NEW YORK, Jan. 13, 2020 (GLOBE NEWSWIRE) — PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced it has received formal notification from the Nasdaq Stock Market LLC (“Nasdaq”) of compliance with Nasdaq Listing Rule 5550(a)(2) after 10 consecutive days with a […]
PAVmed Reports Third Quarter 2019 Financial Results and Provides Business Update
Conference call to be held on November 21, 2019 at 4:30 p.m. Eastern time NEW YORK, Nov. 21, 2019 (GLOBE NEWSWIRE) — PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today reported financial results for the three and nine months ended September […]
PAVmed Names Shaun O’Neil Chief Commercial Officer
NEW YORK–(BUSINESS WIRE)–PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that it has named Shaun M. O’Neil to serve as its first Chief Commercial Officer. Mr. O’Neil will oversee all aspects of the domestic and international commercialization of PAVmed’s products […]
PAVmed to Receive $10.4 Million in Gross Proceeds from Oversubscribed Rights Offering
NEW YORK–(BUSINESS WIRE)–PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced its previously announced equity subscription rights offering (the “Rights Offering”) expired at 5:00 p.m. Eastern Time on Thursday, June 7, 2018 and, as such, the rights are no longer exercisable. The […]
PAVmed Announces Temporary Offer Allowing Warrants to Be Exercised at a Reduced Price
NEW YORK–(BUSINESS WIRE)– PAVmed (Nasdaq: PAVM, PAVMW) (the “Company”), a highly differentiated, multiproduct medical device company, today announced that it intends to temporarily reduce the exercise price of the Company’s outstanding Series W Warrants (Nasdaq: PAVMW, the “Warrants”) to $2.50 per share. The Company intends to file tender offer materials (the “Offer”) […]